Overview
Immunoglobulins are polypeptide molecules produced by plasma cells and are classified into five major types: IgG, IgA, IgM, IgD, and IgE. Each immunoglobulin molecule consists of two identical heavy chains and two identical light chains connected by disulfide bonds. Light chains are of two types, kappa and lambda, with a normal kappa to lambda ratio of approximately 2:1. Restricted expression of either kappa or lambda light chains indicates monoclonality and suggests a neoplastic plasma cell process such as kappa or lambda light chain myeloma. Measurement of kappa light chains plays a key role in assessing plasma cell disorders.
Symptoms
Kappa light chain–related disorders do not produce specific symptoms by themselves; instead, clinical manifestations arise from the underlying plasma cell dyscrasia. Patients may present with features related to multiple myeloma, monoclonal gammopathy of undetermined significance, or primary amyloidosis. These manifestations result from excessive production and accumulation of monoclonal light chains, leading to organ involvement and systemic complications.
Causes
Plasma cell dyscrasias occur when a single plasma cell becomes neoplastic and produces multiple clones of itself within the bone marrow. This clonal proliferation suppresses normal plasma cells and leads to overproduction of a single type of immunoglobulin or free light chain. Free light chains are those not incorporated into intact immunoglobulins and circulate freely in the blood. In monoclonal gammopathies, excessive production of abnormal kappa light chains leads to an altered kappa/lambda ratio and detectable monoclonal protein.
Risk Factors
Conditions associated with abnormal kappa light chain production include multiple myeloma, particularly oligosecretory or non-secretory forms, monoclonal gammopathy of undetermined significance, and monoclonal light chain amyloidosis. Elevated serum free light chain levels and an abnormal kappa/lambda ratio indicate clonal plasma cell activity and are associated with disease burden and progression. Prognostically, free light chain levels above median values have been linked to poorer outcomes in affected patients.
Prevention
There are no established preventive measures to stop the development of kappa light chain–related plasma cell disorders. Prevention focuses on early detection and monitoring. Laboratory evaluation includes measurement of serum free kappa and lambda light chains, assessment of the kappa/lambda ratio, immunofixation electrophoresis, and immunohistochemistry. Sample collection requires blood, urine, bone marrow aspirates, or tissue specimens depending on the test performed. Proper handling and timely transportation of samples are essential to preserve sample integrity. Regular monitoring allows early diagnosis, risk stratification, and timely management to reduce disease-related complications.
